SGLT2 inhibitors SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin) increase urinary glucose excretion and are approved anti-hyperglycemic treatments for T2DM
(Note: If you experience sudden swelling of the lips, face, or throat, or difficulty breathing, seek urgent medical help via 999 or A&E immediately)
Available in a 100 mL vial ready for injection
Since males generally have higher body weight and lean muscle mass, their dosage requirements tend to be higher than females to achieve similar effects
This receptor selectivity makes it an ideal clean GHRH-R agonist for studies where the specific contribution of the GHRH pathway needs to be isolated from ghrelin/GHS-R1a biology
Common approaches include continuous therapy, 5-days-on/2-days-off protocols, or cycling (e.g., 3-6 months on, 1-2 months off)